On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...

RBC Capital analyst Luca Issi lowered the firm’s price target on Crispr Therapeutics (CRSP) to $48 from $53 and keeps a Sector Perform rating ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 61.74% and 252.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...

CRISPR Therapeutics AG (CRSP) closed at $39.41 in the latest trading session, marking a -0.76% move from the prior day.

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...